← Back to Screener
Profound Medical Corp. Common Stock (PROF)
Price$7.15
Favorite Metrics
Price vs S&P 500 (26W)13.28%
Price vs S&P 500 (4W)24.47%
Market Capitalization$331.00M
All Metrics
Book Value / Share (Quarterly)$1.83
P/TBV (Annual)3.30x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)34.06%
Cash Flow / Share (Quarterly)$-1.06
Price vs S&P 500 (YTD)-11.69%
Gross Margin (TTM)70.77%
Net Profit Margin (TTM)-264.45%
EPS (TTM)$-1.41
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-1.41
Revenue Growth (5Y)17.12%
EPS (Annual)$-1.41
ROI (Annual)-60.01%
Gross Margin (Annual)70.77%
Net Profit Margin (5Y Avg)-359.50%
Cash / Share (Quarterly)$1.65
Revenue Growth QoQ (YoY)43.09%
ROA (Last FY)-54.95%
Revenue Growth TTM (YoY)44.35%
EBITD / Share (TTM)$-1.35
ROE (5Y Avg)-58.99%
Operating Margin (TTM)-256.27%
Cash Flow / Share (Annual)$-1.06
P/B Ratio3.64x
P/B Ratio (Quarterly)3.29x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)11.58x
Net Interest Coverage (TTM)-38.77x
ROA (TTM)-73.94%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)12.52x
Quick Ratio (Quarterly)11.02x
3-Month Avg Trading Volume0.02M
52-Week Price Return49.17%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.83
P/S Ratio (Annual)15.01x
Asset Turnover (Annual)0.21x
52-Week High$12.40
Operating Margin (5Y Avg)-376.98%
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)-7.11%
Tangible BV CAGR (5Y)-7.03%
26-Week Price Return22.03%
Quick Ratio (Annual)11.02x
13-Week Price Return-15.15%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)12.52x
Enterprise Value$186.451
Revenue / Share Growth (5Y)4.75%
Asset Turnover (TTM)0.28x
Book Value / Share Growth (5Y)-17.59%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.67x
Pretax Margin (Annual)-262.88%
Cash / Share (Annual)$1.65
3-Month Return Std Dev86.77%
Gross Margin (5Y Avg)57.14%
Net Income / Employee (TTM)$-0
ROE (Last FY)-64.08%
Net Interest Coverage (Annual)-8.13x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)2.36x
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-1.41
Receivables Turnover (Annual)2.36x
ROI (TTM)-82.28%
P/S Ratio (TTM)15.01x
Pretax Margin (5Y Avg)-358.38%
Revenue / Share (Annual)$0.53
Tangible BV / Share (Annual)$1.83
Price vs S&P 500 (52W)14.07%
Year-to-Date Return-8.45%
5-Day Price Return12.81%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-47.90%
Net Profit Margin (Annual)-264.44%
Month-to-Date Return10.79%
Cash Flow / Share (TTM)$-1.82
EBITD / Share (Annual)$-1.35
Operating Margin (Annual)-256.27%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)-52.16%
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)3.30x
P/B Ratio (Annual)3.29x
Inventory Turnover (TTM)0.67x
Pretax Margin (TTM)-262.88%
Book Value / Share (Annual)$1.83
Price vs S&P 500 (13W)-18.01%
Beta2.25x
Revenue / Share (TTM)$0.53
ROE (TTM)-90.28%
52-Week Low$5.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
PROFProfound Medical Corp. Common Stock | 15.01x | 17.12% | 70.77% | -256.27% | $7.15 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Profound Medical develops minimally invasive, image-guided ablation systems for treating prostate disease. Its flagship TULSA-PRO system combines real-time MRI guidance with robotic ultrasound technology to precisely ablate prostate tissue without surgical incisions. The system integrates with hospitals' existing MRI infrastructure, requiring only disposable devices and durable equipment.